Literature DB >> 31881169

Corticosterone in the ventral hippocampus differentially alters accumbal dopamine output in drug-naïve and amphetamine-withdrawn rats.

Brenna Bray1, Kaci A Clement2, Dana Bachmeier3, Matthew A Weber4, Gina L Forster5.   

Abstract

Dysregulation in glucocorticoid stress and accumbal dopamine reward systems can alter reward salience to increase motivational drive in control conditions while contributing to relapse during drug withdrawal. Amphetamine withdrawal is associated with dysphoria and stress hypersensitivity that may be mediated, in part, by enhanced stress-induced corticosterone observed in the ventral hippocampus. Electrical stimulation of the ventral hippocampus enhances accumbal shell dopamine release, establishing a functional connection between these two regions. However, the effects of ventral hippocampal corticosterone on this system are unknown. To address this, a stress-relevant concentration of corticosterone (0.24ng/0.5 μL) or vehicle were infused into the ventral hippocampus of urethane-anesthetized adult male rats in control and amphetamine withdrawn conditions. Accumbal dopamine output was assessed with in vivo chronoamperometry. Corticosterone infused into the ventral hippocampus rapidly enhanced accumbal dopamine output in control conditions, but produced a biphasic reduction of accumbal dopamine output in amphetamine withdrawal. Selectively blocking glucocorticoid-, mineralocorticoid-, or cytosolic receptors prevented the effects of corticosterone. Overall, these results suggest that the ability of corticosterone to alter accumbal dopamine output requires cooperative activation of mineralocorticoid and glucocorticoid receptors in the cytosol, which is dysregulated during amphetamine withdrawal. These findings implicate ventral hippocampal corticosterone in playing an important role in driving neural systems involved in positive stress coping mechanisms in healthy conditions, whereas dysregulation of this system may contribute to relapse during withdrawal.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Corticosterone; Dopamine; Glucocorticoid receptors; Nucleus accumbens shell; Psychostimulant withdrawal; Ventral hippocampus

Year:  2019        PMID: 31881169      PMCID: PMC7103421          DOI: 10.1016/j.neuropharm.2019.107924

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  122 in total

Review 1.  Dissecting motivational circuitry to understand substance abuse.

Authors:  Robert A Wheeler; Regina M Carelli
Journal:  Neuropharmacology       Date:  2008-06-25       Impact factor: 5.250

2.  NMDA and non-NMDA receptors are co-localized at individual excitatory synapses in cultured rat hippocampus.

Authors:  J M Bekkers; C F Stevens
Journal:  Nature       Date:  1989-09-21       Impact factor: 49.962

3.  Serotonergic neurotransmission in the ventral hippocampus is enhanced by corticosterone and altered by chronic amphetamine treatment.

Authors:  J L Barr; G L Forster
Journal:  Neuroscience       Date:  2011-03-21       Impact factor: 3.590

Review 4.  On the motivational properties of reward cues: Individual differences.

Authors:  Terry E Robinson; Lindsay M Yager; Elizabeth S Cogan; Benjamin T Saunders
Journal:  Neuropharmacology       Date:  2013-06-07       Impact factor: 5.250

5.  Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells.

Authors:  Jamie D Croxtall; Peter Th W van Hal; Qam Choudhury; Derek W Gilroy; Rod J Flower
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 6.  Mifepristone (RU486): a review.

Authors:  D K Mahajan; S N London
Journal:  Fertil Steril       Date:  1997-12       Impact factor: 7.329

7.  Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons.

Authors:  S B Floresco; C L Todd; A A Grace
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

Review 8.  The role of stress in addiction relapse.

Authors:  Rajita Sinha
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

Review 9.  Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists.

Authors:  Cindy Stahn; Mark Löwenberg; Daniel W Hommes; Frank Buttgereit
Journal:  Mol Cell Endocrinol       Date:  2007-06-02       Impact factor: 4.102

10.  Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli.

Authors:  Mark A Ungless; Peter J Magill; J Paul Bolam
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.